Fresh frozen plasma must be given 10-20 ml/kg every 8-12 h in order to replace the procoagulant
and anticoagulant proteins consumed in the disease process.
Their use is based on the rationale that congenital deficiencies in any of the procoagulant
factors translate into defective thrombin generation and, hence, into defective fibrinogen-to fibrin conversion and prolonged PT or APTT.
Elevated levels of shed membrane microparticles with procoagulant
potential in the peripheral circulating blood of patients with acute coronary syndromes.
Platelets provide a procoagulant
surface for amplification of cancer-related coagulation.
Ozsoylu has already specified, due to the coagulation being dependant on the dynamic balance between procoagulant
and fibrinolytic activity, fibrinolytic system could have been evaluated as well.
In addition to all these factors, increase in production of tumor necrosis factor (15) and decrease in production of glycosaminoglucan in the intestines may also have procoagulant
CD40 engagement on endothelial cells promotes tissue factor-dependent procoagulant
In addition, elevated biomarkers of inflammation (increased IL-6, CRP) and procoagulant
effects (in vivo platelet activation, elevated D-dimer) developed in asymptomatic AMAA runners during races, indicates a transient susceptibility to atherothrombosis.
In this study, we examined if both compounds affected the expression of the procoagulant
tissue factor (TF) induced by lipopolysaccharide (LPS) on human monocyte.
Cushing's disease is known to carry risks for arterial and venous thrombosis, given the typical accompanying increases in procoagulant
factors and reduced fibrinolytic activity (12).
There have been promising reports of the use of recombinant factor VIIa (rVIIa) for treating hemorrhage in patients with AFE in recent years, but a recent review of case reports of AFE from 2003 to 2009 suggests that the procoagulant
may actually worsen outcomes (Anesthesiology 2011;115:1201-8).
Use of procoagulant
reversal agents such as prothrombin complex concentrate (PCC), activated prothrombin complex concentrate (APCC), or recombinant factor VIIa (rFVIIa) may be considered, but has not been evaluated in clinical trials.